Cell death plays an important role both in shaping the developing nervous system and in neurological disease and traumatic injury. In spite of their name, death receptors can trigger either cell death or survival and growth. Recent studies implicate five death receptors -Fas/CD95, TNFR1 (tumor necrosis factor receptor-1), p75 NTR (p75 neurotrophin receptor), DR4, and DR5 (death receptors-4 and -5) -in different aspects of neural development or degeneration. Their roles may be neuroprotective in models of Parkinson's disease, or pro-apoptotic in ALS and stroke. Such different outcomes probably reflect the diversity of transcriptional and posttranslational signaling pathways downstream of death receptors in neurons and glia. 
Introduction
The term 'death receptor' refers to a group of eight members of the TNFR superfamily of single-pass transmembrane proteins [1] . The death receptors are the only members of this family whose cytoplasmic tail contains a conserved 80-amino acid sequence referred to as the 'death domain'. In the appropriate cellular context, activation of a death receptor leads to formation of a deathinducing signaling complex (DISC) at the death domain and subsequent triggering of downstream cascades leading to death of the cell which expresses the receptor [1, 2 ] . Physiologically, death receptor activation can occur in cis, by transmembrane ligand expressed in the same cell as the receptor, or in trans, by ligand expressed at the surface of other cells or released into the extracellular milieu.
This review will focus on five death receptors and their ligands for which new roles in the nervous system have been reported over the past two years. FasL/CD95L triggers cell death through its receptor Fas/CD95 by recruiting the adapter protein FADD (Fas-associated death domain) and pro-caspase-8. This ligand-receptor couple will be simply referred to as FasL and Fas in the body of the review. TNFa (tumor necrosis factor alpha) acts as a soluble homotrimer through two TNFR family members: TNFR1, which has a death domain, and TNFR2, which does not. Death signaling by TNFR1 involves recruitment of adapter signaling molecules TRADD (TNFR-associated death domain), FADD, and RIP (receptor interacting protein). Death receptors -4 and -5 (DR4 and DR5) share the same ligand -TRAIL (TNF-related apoptosis-inducing ligand) -and signal in a similar manner to Fas. Lastly, p75 NTR can signal cell death when bound by NGF (nerve growth factor) or other ligands. Like the other 30 members of the TNFR family, death receptors also play multiple roles in cell differentiation, growth, and proliferation [2 ] . We will highlight examples of these as a reminder that expression of a death receptor in a given tissue does not necessarily imply a role in degeneration or death.
Death receptors in nervous system development Death receptors and their ligands are expressed in the developing nervous system, and many recent reports confirm their ability to trigger death of embryonic neurons and glia in vitro [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . However, with the exception of earlier reports concerning p75 NTR , there is still relatively little evidence that death receptors play a role in nervous system development in vivo. This may be because they mostly regulate phenomena other than cell death at this stage. The spontaneous mouse mutants, lpr and gld, which are partial loss-of-function mutants for Fas and FasL, respectively, have normal numbers of cortical, hippocampal, and motor neurons at birth [16, 17 ] . However, they do show reduced dendritic branching of hippocampal and cortical neurons during the period in which synaptogenesis is occurring [17 ] . At similar stages, mice deficient in TNFa, which is normally produced by glia, show defects in synaptic scaling and ocular dominance plasticity in the visual system [18, 19] . However, a full understanding of the overall role of death receptors in nervous system development will require a more systematic approach in null mutant mice.
Involvement of death receptors in disease mechanism and therapeutic strategies in ALS
There is now a considerable body of data pointing to a role for death receptors in pathological situations. This provides new opportunities for therapeutic intervention, focused on the death receptors themselves, their ligands, or intracellular relays. Many pharmacological compounds, recombinant proteins, and genetic strategies have therefore been designed and tested in rodent models of disease. Recent reports are summarized in Table 1 .
Currently the best evidence of a role for death receptors in neurological diseases comes from the study of amyotrophic lateral sclerosis (ALS). In patients with ALS, degeneration and death of motor neurons in the spinal cord lead to progressive and fatal muscle paralysis. Much of our understanding of the underlying mechanisms comes from studies of transgenic mice overexpressing toxic mutant forms of SOD1 (Cu, Zn-superoxide dismutase-1), which cause ALS in a subset of patients with a familial form of the disease. Mutant SOD1 triggers neurodegeneration in a cell-autonomous fashion in motor neurons, but also drives disease progression through non-autonomous mechanisms involving microglia and astrocytes [20 -22 ] . Three death receptors -TNFa, p75 NTR , and Fas/CD95 -have been implicated in cellautonomous and/or non-autonomous aspects of the disease.
Upregulation of TNFa and TNF receptors is observed in parallel with the appearance of symptoms in SOD1 mice [23, 24] and increased levels of TNFa are found in plasma of ALS patients [25] . However, genetic ablation of TNFa The Table summarizes recent in vivo studies targeting the nervous system, grouping them by target -ligand, receptor, or effector -and by the pathology that they most closely model. Genetic gain-or loss-of-function or pharmacological approaches have provided important validation (or invalidation) of mechanisms identified in vitro, and can also serve as proof-of-principle for subsequent therapeutic strategies. The principal outcomes of these interventions are described in the text. Abbreviations: MPTP (1-methyl-4-phenyl 1,2,3,6-tetrahydropyridine); SNA (sciatic nerve avulsion); MCAO (middle cerebral artery occlusion); lpr (lymphoproliferative); gld (generalized lymphoproliferative disease); JEV (Japanese Encephalitis Virus).
has no beneficial effect on survival, motor axon degeneration or gliosis in either of two different lines of mutant SOD1 mice [26 ] . Although application of recombinant TNF-binding protein-1 (rhTBP-1) had protective effects in wobbler mice -another model of motor neuron degeneration -the treatment did not in fact reduce TNFa levels in the CNS [27] . In mutant SOD1 mice, the beneficial effects of treatments as diverse as thalidomide, folic acid, insulin-like growth factor-1, and metal chelators are all correlated in SOD1 mice with reductions in TNFa levels [28] [29] [30] [31] . However, it does not seem likely that they all act through TNFa/TNFR directly to prevent degeneration; the reductions more probably reflect a decrease in inflammation secondary to neuroprotection by other mechanisms. Given the lack of evidence for a direct role in motor neuron death, an interesting possibility is that TNFa may trigger the redistribution of axonal mitochondria known to occur in ALS motor neurons in vivo More indirect evidence of a role for Fas comes from studies of the matrix metalloproteinases (MMPs), which are involved in the proteolytic processing of TNFa and FasL from precursor to soluble forms. Inhibition of MMPs with the broad spectrum inhibitor Ro28-2653 had some positive effects in mutant SOD1 mice [42] . However, genetic knockout of MMP-9 attenuated disease in one study [37] but exacerbated symptoms in another [43] . Tissue inhibitors of metalloproteinases can signal through MMP inhibition to enhance stabilization and activation of death receptors such as Fas. One member of this family, TIMP-3, is strongly upregulated in degenerating motor neurons in spinal cords of SOD1 mice [38] .
Overall, therefore, there is intriguing presumptive evidence that Fas signaling may play a role in ALS, but more data from genetic studies in mice and human patients are required to support this hypothesis.
Death receptors in other diseases and degenerative processes in the nervous system
In models of Alzheimer's disease, death receptor signaling may potentially play a role both upstream and downstream of accumulation of the Ab (amyloid-beta) peptide. TNFa stimulates expression of BACE1 (betasite amyloid precursor protein-cleaving enzyme-1) and consequently production of Ab [44] . In turn, cell death of septohippocampal neurons induced by Ab in vitro and in vivo requires the presence of p75 NTR [12] . Data from several different models of spinal cord injury, axotomy, deafferentation, and ischemia provide strong evidence that Fas activation has a deleterious effect on the survival of injured neurons [15, 16, [45] [46] [47] [48] . By contrast, in the MPTP model of Parkinson's disease, Fas activation protects dopaminergic neurons from MPTP toxicity, providing the first in vivo evidence that death receptors can act to enhance neuronal survival [49] . In the same MPTP model, TNFa has opposite effects depending on the cell context: it is protective for hippocampal neurons, but triggers degeneration of dopaminergic axons [50] . These results exemplify the importance of cellular context in determining whether death receptor signaling is pro-or anti-apoptotic.
Signaling mechanisms downstream of death receptors in neural systems
The generality of the classical model involving activation of caspases and mitochondrial pro-apoptotic factors through formation of a DISC is currently questioned [2 ] . It has been particularly challenged by two sets of results in the nervous system: (a) demonstrated requirements for novel signaling and transcriptional events in the execution of neuronal death; and (b) unexpected outcomes of death receptor activation such as cell survival and neurite outgrowth [2 ] . These are summarized for dying and healthy neurons and glia in Figure 1 .
Involvement of stress-activated protein (SAP) kinases represents the first layer of complexity superimposed on the prototypic death receptor pathway. Depending on the cellular context, different SAP kinases are involved. To kill motor neurons, Fas needs to selectively activate p38 kinase but not JNK (c-Jun N-terminal kinase) [35] . This in turn leads to obligate transcriptional upregulation of neuronal nitric oxide synthase [10 ] . DR4 acts through JNK3 but not p38 kinase to trigger oligodendrocyte apoptosis [6], whereas TNFR1 in neuroblastoma cells signals through both JNK and p38 kinase [13] . p75 NTR death signaling also shows cell type-dependent complexities. Production of ceramide by neutral sphingomyelinase is an obligatory step for caspase activation in NGF-treated motor neurons [8] whereas in sensory neurons, p75 NTR elicits potassium efflux through phosphatidylinositol-4,5-biphosphate-dependent activation of G protein-coupled inward rectifier potassium (GIRK) channels [4 ] .
In spite of their name, death receptors can activate nonapoptotic pathways in appropriate cellular contexts, and are indeed required for cell survival and tissue regeneration in several systems [2 ,49] . Fas-induced branching of cortical and hippocampal and sensory neurons does not require caspase activation [17 ] . In agreement with this, Fas-triggered axonal outgrowth involves activation of the MEK1/ERK1/p35 pathway in sensory neurons and of the Ezrin-Rac1 pathway in cortical neurons [51] .
Control of death receptor signaling can occur at multiple levels. In neurons, both Fas and TNFR localize to lipid rafts, specialized microdomains of the plasma membrane, and such localization seems to be required for death signaling [5] . Neuronal cell death induced by p75 NTR requires palmitoylation, translocation to lipid rafts, and metalloproteinase cleavage of the extracellular domain [14] . In agreement with the emerging importance of subcellular compartmentalization of death signaling pathways, proteomic analysis of reverse signaling through FasL reveals interactors associated with endocytosis and trafficking [52] . There are diverse alternative mechanisms for control of the outcome of death receptor activation. Regulation of Fas or TRAIL-R2/DR5 can occur at the transcriptional level in a p53-dependent manner [15, 37, 46] . 
Conclusions
Our vision of death receptor signaling has radically changed over the past decade, as the many data pointing to 'positive' signaling outcomes such as growth or survival have been progressively taken into account. Cellular context strongly affects the choice of outcome in the nervous system and potential molecular mechanisms to explain this -alternative co-receptors, interaction with other signaling pathways -need to be further investigated. Nevertheless, the classical role of death receptors as triggers of degeneration and cell death seems to come into play in several forms of neurodegeneration, particularly ALS and stroke. New genetic and pharmacological tools will allow these hypotheses to be more fully tested in vivo.
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